Olmesartan Medoxomil Mcdermott Laboratories (Olmesartan Medoxomil)

• Olmesartan Medoxomil is an ARB used to manage elevated blood pressure within the hypertension disease family.
• Essential hypertension: lowers systolic and diastolic pressure to target levels.
• Isolated systolic hypertension: reduces high systolic readings, especially in older adults.
• Controlled hypertension (as part of combination therapy): helps achieve blood pressure goals when used with other antihypertensives.

• Olmesartan Medoxomil is a selective antagonist of angiotensin II type 1 (AT1) receptors. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to vasodilation, reduced sodium and water retention, and ultimately a decrease in systemic blood pressure.

Olmesartan Medoxomil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nausea
• Back pain
• Diarrhoea

Serious or Rare Side Effects

• Angioedema (swelling of face, lips, tongue)
• Acute renal impairment
• Hyperkalaemia (elevated potassium)
• Severe hypotension
• Liver enzyme elevations
• Myocardial infarction (rare)

When prescribing Olmesartan Medoxomil, clinicians should consider several safety measures.

• Renal function monitoring: assess serum creatinine and eGFR periodically.
• Serum potassium monitoring: avoid hyperkalaemia, especially with potassium‑sparing agents.
• Hepatic impairment: use with caution in patients with liver disease.
• Hypersensitivity: discontinue if signs of angioedema or rash appear.
• Concomitant aliskiren in diabetes: avoid due to increased renal risk.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Olmesartan Medoxomil can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal dysfunction.
• Dual therapy with ACE inhibitors: heightened risk of angioedema and renal impairment.
• Potassium‑sparing diuretics (e.g., spironolactone): may cause severe hyperkalaemia.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Lithium: can raise lithium serum levels, risking toxicity.
• Loop or thiazide diuretics: may enhance hypotensive response.
• CYP450 inhibitors (e.g., ketoconazole): modest increase in plasma concentrations.